Rapamycin induces the anti-apoptotic protein survivin in neuroblastoma

International Journal of Biochemistry and Molecular Biology

Volumn 3, Issue 1, 2012, Pages 28-35

  Samkari, Ayman ^a   Cooper, Zachary A ^a   Holloway, Michael P ^a   Liu, Jiebin ^a   Altura, Rachel A ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

HSP90; mTOR; Neuroblastoma; Rapamycin; Survivin

Indexed keywords

HEAT SHOCK PROTEIN 90; LIPOCORTIN 5; MESSENGER RNA; RAPAMYCIN; SURVIVIN;

APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL CYCLE ARREST; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; GENE; GENE EXPRESSION REGULATION; GENETIC STABILITY; HUMAN; HUMAN CELL; LUNG CANCER; MOLECULAR DYNAMICS; NEUROBLASTOMA; NEUROBLASTOMA CELL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN STABILITY; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SURVIVIN GENE; WESTERN BLOTTING;

MAMMALIA;

EID: 84859713686     PISSN: None     EISSN: 21524114     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Park JR, Eggert A and Caron H. Neuroblastoma: biology, prognosis, and treatment. Hematol Oncol Clin North Am 2010; 24: 65-86.
2. Triche TJ. Neuroblastoma--biology confronts nosology. Arch Pathol Lab Med 1986; 110: 994-996.
3. Brodeur GM, Seeger RC, Barrett A, Berthold F, Castleberry RP, D'Angio G, De Bernardi B, Evans AE, Favrot M, Freeman AI. International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. J Clin Oncol 1988; 6: 1874-1881.
4. Castle VP, Heidelberger KP, Bromberg J, Ou X, Dole M and Nunez G. Expression of the apoptosis-suppressing protein bcl-2, in neuroblastoma is associated with unfavorable histology and N-myc amplification. Am J Pathol 1993; 143: 1543-1550.
5. Altieri DC. Molecular circuits of apoptosis regulation and cell division control: the survivin paradigm. J Cell Biochem 2004; 92: 656-663.
6. Li F. Survivin study: what is the next wave? J Cell Physiol 2003; 197: 8-29.
7. Islam A, Kageyama H, Takada N, Kawamoto T, Takayasu H, Isogai E, Ohira M, Hashizume K, Kobayashi H, Kaneko Y and Nakagawara A. High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene 2000; 19: 617-623.
8. Miller MA, Ohashi K, Zhu X, McGrady P, London WB, Hogarty M and Sandler AD. Survivin mRNA levels are associated with biology of disease and patient survival in neuroblastoma: a report from the children's oncology group. J Pediatr Hematol Oncol 2006; 28: 412-417.
9. Altieri DC. New wirings in the survivin networks. Oncogene 2008; 27: 6276-6284.
10. Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 2008; 8: 61-70.
11. Blanc-Brude OP, Mesri M, Wall NR, Plescia J, Dohi T and Altieri DC. Therapeutic targeting of the survivin pathway in cancer: initiation of mitochondrial apoptosis and suppression of tumor-associated angiogenesis. Clin Cancer Res 2003; 9: 2683-2692.
12. Zoncu R, Efeyan A and Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011; 12: 21-35.
13. Fulda S. The PI3K/Akt/mTOR pathway as therapeutic target in neuroblastoma. Curr Cancer Drug Targets 2009; 9: 729-737.
14. Thomas GV, Tran C, Mellinghoff IK, Welsbie DS, Chan E, Fueger B, Czernin J and Sawyers CL. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 2006; 12: 122-127.
15. Chu R, Zhao X, Griffin C, Staub RE, Shoemaker M, Climent J, Leitman D, Cohen I, Shtivelman E and Fong S. Selective concomitant inhibition of mTORC1 and mTORC2 activity in estrogen receptor negative breast cancer cells by BN107 and oleanolic acid. Int J Cancer 2010; 127: 1209-1219.
16. Masri J, Bernath A, Martin J, Jo OD, Vartanian R, Funk A and Gera J. mTORC2 activity is elevated in gliomas and promotes growth and cell motility via overexpression of rictor. Cancer Res 2007; 67: 11712-11720.
17. Giles FJ, Albitar M. Mammalian target of rapamycin as a therapeutic target in leukemia. Curr Mol Med 2005; 5: 653-661.
18. Nagata Y, Takahashi A, Ohnishi K, Ota I, Ohnishi T, Tojo T and Taniguchi S. Effect of rapamycin, an mTOR inhibitor, on radiation sensitivity of lung cancer cells having different p53 gene status. Int J Oncol 2010; 37: 1001-1010.
19. Witton CJ. Determining sensitivity to rapamycin and its analogues in breast cancer patients. Breast Cancer Res 2005; 7: 41-42.
20. Spunt SL, Grupp SA, Vik TA, Santana VM, Greenblatt DJ, Clancy J, Berkenblit A, Krygowski M, Ananthakrishnan R, Boni JP and Gilbertson RJ. Phase I study of temsirolimus in pediatric patients with recurrent/refractory solid tumors. J Clin Oncol 2011; 29: 2933-2940.
21. Izycka-Swieszewska E, Drozynska E, Rzepko R, Kobierska-Gulida G, Grajkowska W, Perek D and Balcerska A. Analysis of PI3K/AKT/mTOR signalling pathway in high risk neuroblastic tumours. Pol J Pathol 2010; 61: 192-198.
22. Johnsen JI, Segerstrom L, Orrego A, Elfman L, Henriksson M, Kagedal B, Eksborg S, Sveinbjornsson B and Kogner P. Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo. Oncogene 2008; 27: 2910-2922.
23. Decker T, Hipp S, Ringshausen I, Bogner C, Oelsner M, Schneller F and Peschel C. Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin. Blood 2003; 101: 278-285.
24. Yao C, Liu J and Shao L. Rapamycin inhibits the proliferation and apoptosis of gastric cancer cells by down regulating the expression of survivin. Hepatogastroenterology 2011; 58: 1075-1080.
25. Chen B, Yuping S and Ni J. Rapamycin decreases survivin expression to induce NSCLC cell apoptosis under hypoxia through inhibiting HIF-1alpha induction. Mol Biol Rep 2012; 39: 185-191.
26. Niu H, Wang J, Li H and He P. Rapamycin potentiates cytotoxicity by docetaxel possibly through downregulation of Survivin in lung cancer cells. J Exp Clin Cancer Res 2011; 30: 28.
27. Azuhata T, Scott D, Takamizawa S, Wen J, Davidoff A, Fukuzawa M and Sandler A. The inhibitor of apoptosis protein survivin is associated with high-risk behavior of neuroblastoma. J Pediatr Surg 2001; 36: 1785-1791.
28. Vassal G, Terrier-Lacombe MJ, Bissery MC, Venuat AM, Gyergyay F, Benard J, Morizet J, Boland I, Ardouin P, Bressac-de-Paillerets B and Gouyette A. Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts. Br J Cancer 1996; 74: 537-545.
29. Giard DJ, Aaronson SA, Todaro GJ, Arnstein P, Kersey JH, Dosik H and Parks WP. In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. J Natl Cancer Inst 1973; 51: 1417-1423.
30. Niu H, Wang J, Li H and He P. Rapamycin potentiates cytotoxicity by docetaxel possibly through downregulation of Survivin in lung cancer cells. J Exp Clin Cancer Res 2011; 30: 28.
31. Trepel J, Mollapour M, Giaccone G and Neckers L. Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 2010; 10: 537-549.
32. Fortugno P, Beltrami E, Plescia J, Fontana J, Pradhan D, Marchisio PC, Sessa WC and Altieri DC. Regulation of survivin function by Hsp90. Proc Natl Acad Sci USA 2003; 100: 13791-13796.
33. Nissen E, Pauli G and Vollenbroich D. WST-1 assay--a simple colorimetric method for virus titration. In Vitro Cell Dev Biol Anim 1997; 33: 28-29.
34. Ries LAG, Smith MA, Gurney JG, Linet M, Tamra T, Young JL, Bunin GR (eds). Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995, National Cancer Institute, SEER Program. NIH Pub. No. 99-4649. Bethesda, MD, 1999.
35. Maris JM. Recent advances in neuroblastoma. N Engl J Med 2010; 362: 2202-2211.
36. Cheung NV, Heller G. Chemotherapy dose intensity correlates strongly with response, median survival, and median progression-free survival in metastatic neuroblastoma. J Clin Oncol 1991; 9: 1050-1058.
37. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, Swift P, Shimada H, Black CT, Brodeur GM, Gerbing RB and Reynolds CP. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999; 341: 1165-1173.
38. Simon T, Hero B, Faldum A, Handgretinger R, Schrappe M, Niethammer D and Berthold F. Consolidation treatment with chimeric anti-GD2 -antibody ch14.18 in children older than 1 year with metastatic neuroblastoma. J Clin Oncol 2004; 22: 3549-3557.
39. Misawa A, Hosoi H, Tsuchiya K and Sugimoto T. Rapamycin inhibits proliferation of human neuroblastoma cells without suppression of MycN. Int J Cancer 2003; 104: 233-237.
40. Moriai R, Tsuji N, Moriai M, Kobayashi D and Watanabe N. Survivin plays as a resistant factor against tamoxifen-induced apoptosis in human breast cancer cells. Breast Cancer Res Treat 2009; 117: 261-271.
41. Tirro E, Consoli ML, Massimino M, Manzella L, Frasca F, Sciacca L, Vicari L, Stassi G, Messina L, Messina A and Vigneri P. Altered expression of c-IAP1, survivin, and Smac contributes to chemotherapy resistance in thyroid cancer cells. Cancer Res 2006; 66: 4263-4272.
42. Krysan K, Merchant FH, Zhu L, Dohadwala M, Luo J, Lin Y, Heuze-Vourc'h N, Pold M, Seligson D, Chia D, Goodglick L, Wang H, Strieter R, Sharma S and Dubinett S. COX-2-dependent stabilization of survivin in non-small cell lung cancer. FASEB J 2004; 18: 206-208.
43. Hayashi N, Asano K, Suzuki H, Yamamoto T, Tanigawa N, Egawa S and Manome Y. Adenoviral infection of survivin antisense sensitizes prostate cancer cells to etoposide in vivo. Prostate 2005; 65: 10-19.
44. Rodel C, Haas J, Groth A, Grabenbauer GG, Sauer R and Rodel F. Spontaneous and radiation-induced apoptosis in colorectal carcinoma cells with different intrinsic radiosensitivities: survivin as a radioresistance factor. Int J Radiat Oncol Biol Phys 2003; 55: 1341-1347.
45. Chakravarti A, Zhai GG, Zhang M, Malhotra R, Latham DE, Delaney MA, Robe P, Nestler U, Song Q and Loeffler J. Survivin enhances radiation resistance in primary human glioblastoma cells via caspase-independent mechanisms. Oncogene 2004; 23: 7494-7506.
46. Zhao R, Davey M, Hsu YC, Kaplanek P, Tong A, Parsons AB, Krogan N, Cagney G, Mai D, Greenblatt J, Boone C, Emili A and Houry WA. Navigating the chaperone network: an integrative map of physical and genetic interactions mediated by the hsp90 chaperone. Cell 2005; 120: 715-727.
47. Trepel J, Mollapour M, Giaccone G and Neckers L. Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 2010; 10: 537-549.
48. Regan PL, Jacobs J, Wang G, Torres J, Edo R, Friedmann J and Tang XX. Hsp90 inhibition increases p53 expression and destabilizes MYCN and MYC in neuroblastoma. Int J Oncol 2011; 38: 105-112.